# NextCure (NXTC) — Earnings

NXTC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nxtc/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$11.29 |
| EPS estimate | −$4.62 |
| EPS surprise | −144.64% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 7, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1661059/000155837025010782/nxtc-20250630x10q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 7, 2025 | −$4.62 | −$11.29 | -144.64% | — | — |
| Q1 2025 | May 1, 2025 | −$4.80 | −$4.68 | 2.50% | — | — |
| Q4 2024 | Mar 6, 2025 | −$4.32 | −$5.04 | -16.67% | — | — |
| Q3 2024 | Nov 7, 2024 | −$4.14 | −$4.92 | -18.84% | — | — |
| Q2 2024 | Aug 1, 2024 | −$4.52 | −$6.60 | -46.02% | — | — |
| Q1 2024 | May 2, 2024 | −$5.52 | −$7.32 | -32.61% | — | — |
| Q4 2023 | Mar 21, 2024 | −$6.50 | −$6.24 | 4.04% | — | — |
| Q3 2023 | Nov 2, 2023 | −$7.89 | −$6.12 | 22.43% | — | — |
| Q2 2023 | Aug 3, 2023 | −$6.63 | −$7.68 | -15.82% | — | — |
| Q1 2023 | May 4, 2023 | −$7.44 | −$6.96 | 6.42% | — | — |
| Q4 2022 | Mar 2, 2023 | −$7.88 | −$7.44 | 5.53% | — | — |
| Q3 2022 | Nov 3, 2022 | −$7.34 | −$8.16 | -11.17% | — | — |
| Q2 2022 | Aug 4, 2022 | −$8.64 | −$7.80 | 9.72% | — | — |
| Q1 2022 | May 5, 2022 | −$8.02 | −$8.88 | -10.72% | — | — |
| Q4 2021 | Mar 3, 2022 | −$8.04 | −$7.32 | 9.00% | — | — |
| Q3 2021 | Nov 4, 2021 | −$8.00 | −$7.80 | 2.55% | — | — |
| Q2 2021 | Aug 5, 2021 | −$7.34 | −$7.80 | -6.31% | — | — |
| Q1 2021 | May 6, 2021 | −$7.06 | −$7.20 | -1.98% | — | — |
| Q4 2020 | Mar 4, 2021 | −$7.13 | −$6.48 | 9.16% | — | — |
| Q3 2020 | Nov 5, 2020 | −$6.87 | −$7.08 | -2.99% | — | — |

## Frequently Asked Questions

### When did NextCure (NXTC) last report earnings?

NextCure last reported on Aug 7, 2025, covering fiscal Q2 2025.

### Did NXTC beat earnings estimates?

No. NextCure reported EPS of −$11.29 for Q2 2025 against a −$4.62 estimate — a 144.64% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).